Here’s another terrific post by Pharmboy, this time discussing Generic Drug Makers. - Ilene Generic Drug Makers Courtesy of Pharmboy Coming to the end of a good year, and good riddance for some!  Whilst the market has been irrational for some time, it is not about what we think but rather about what others that have money think.  I have my notions, and here are a few companies that may do well in the New Year with a passed health care reform bill. I really like the generic market right now. With patents expiring you can literally gauge how much a generic will make based on the patents expiring in the next few months. These generics are the vultures that follow the in a pack of lions.  They have a good way of scavenging for their food and vultures have a distinct relationship with the lions.  They may not come up with the drugs but they are definitely going to make a nice margin from them.  But the competition is fierce these days, and competitors in the generic market include Watson ( WPI ), Teva ( TEVA ) , Dr Reddy’s Labs ( RDY ), Hi-Tech Pharmacal ( HITK ), Par Pharmaceuticals ( PRX ), and Caraco ( CPD ). First up, Mylan Pharmaceuticals ( MYL ) - I know that Phil has liked Teva in the past and I have noted Mylan (#3 in generics), WPI and RDY (pre-GSK rumors).  Currently, Mylan has blown through its 52 week high so is it still a buy?  In short answer, yes.  Mylan’s future comes from a swath of FDA approvals that have come in over the past few months. August 27, 2009 Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment August 18, 2009 Mylan’s Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment August 10, 2009 Mylan Receives FDA Approval for Generic Version of Migraine Treatment Imitrex(R) July 20, 2009 Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol — Key News from the article. Currently, Mylan has 119 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health. July 16, 2009 Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel July 7, 2009 Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex June 17, 2009 Mylan Receives FDA Approval for Additional Strength of Generic…